UPC
Universe Pharmaceuticals INC
Next earnings Jul 20, 2026
$6.32
▼ -48.11%$6.32▲ +73.15%
over 1Y
L $2.25H $12.18
Today-48.1%
1W—
1M—
3M—
YTD—
1Y—
Avoid
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -22.4% YoY.
Revenue (FY2025) $17.9B · FY2025
Universe Pharmaceuticals INC shows $17.9B in FY2025 revenue (-22.4% YoY), a -20.6% net margin, and -6.5% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.23x).
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 7:50 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $48.0M | $40.1M | $32.3B | $23.0B | $17.9B |
| Gross profit | $25.3M | $21.9M | $10.3B | $6.07B | $6.30B |
| Operating income | $13.6M | -$7.02M | -$3.97B | -$8.02B | -$2.92B |
| Net income | $11.3M | -$7.91M | -$6.58B | -$8.73B | -$3.67B |
| Diluted EPS | $3.58 | -$1,309.11 | -$1,089.21 | -$626.96 | -$8.06 |
| Net margin | 23.6% | -19.7% | -20.4% | -37.9% | -20.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$31.5B
EV / EBITDA—
EV / Sales-1.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-87514.4%
FCF yield-126767.5%
Quality & risk
ROIC (est.)-4.0%
Free cash flow-$5.32B
Total debt$2.11B
Net cash$31.5B
Altman Z-Score0.54 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)381.4%
Shareholder yield381.4%
Shares Δ YoY-97.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-262026-06-26open ↗4Period ending 2026-05-072026-05-21open ↗SCHEDULE 13DFiling2026-05-21open ↗6-KPeriod ending 2026-05-142026-05-14open ↗6-KPeriod ending 2026-04-162026-04-16open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗6-KPeriod ending 2026-02-112026-02-11open ↗
Frequently asked
- Is Universe Pharmaceuticals INC (UPC) a buy?
- UPC currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -22.4% YoY.
- What is Universe Pharmaceuticals INC's quality score?
- UPC scores 48.538748060279744/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001809616, latest 6-K filed 2026-06-26) · EODHD · as of 7/4/2026, 11:50:51 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.